Is Genomic Risk Stratification useful for Patients with early HR+/ERBB2 Breast Cancer?

被引：0
|
作者：
Lichert, Frank
机构：
来源：
GEBURTSHILFE UND FRAUENHEILKUNDE | 2023年 / 83卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
引用
收藏
页码：474 / 474
页数：1
相关论文
共 50 条
  • [31] Identification of a small peptide that inhibits the phosphorylation of ErbB2 and proliferation of ErbB2 overexpressing breast cancer cells
    Pero, SC
    Shukla, GS
    Armstrong, AL
    Peterson, D
    Fuller, SP
    Godin, K
    Kingsley-Richards, SL
    Weaver, DL
    Bond, J
    Krag, DN
    INTERNATIONAL JOURNAL OF CANCER, 2004, 111 (06) : 951 - 960
  • [32] Genomic And Transcriptomic Profiling of Primary Tumors From Patients with HR+, HER2-, Node-positive, High-risk Early Breast Cancer (EBC) in the monarchE Trial
    Rubenstein, C. S.
    Turner, N.
    Reis-Filho, J. S.
    Goetz, M. P.
    Desmedt, C.
    Chandarlapaty, S.
    Sasano, H.
    Arteaga, C. L.
    Loi, S.
    Graff, S. L.
    Liu, D.
    Rodrik-Outmezguine, V.
    Sireci, A.
    Won, H.
    Litchfield, L. M.
    Munoz, M.
    Johnston, S.
    BREAST, 2025, 80
  • [33] Incorporating clinicopathological and molecular risk prediction tools to improve outcomes in early HR+/HER2- breast cancer
    Curigliano, Giuseppe
    Dent, Rebecca
    Llombart-Cussac, Antonio
    Pegram, Mark
    Pusztai, Lajos
    Turner, Nicholas
    Viale, Giuseppe
    NPJ BREAST CANCER, 2023, 9 (01)
  • [34] Incorporating clinicopathological and molecular risk prediction tools to improve outcomes in early HR+/HER2– breast cancer
    Giuseppe Curigliano
    Rebecca Dent
    Antonio Llombart-Cussac
    Mark Pegram
    Lajos Pusztai
    Nicholas Turner
    Giuseppe Viale
    npj Breast Cancer, 9
  • [35] Risk stratification based on a prognostic factor index among patients with HR+, HER2-MBC.
    Vidal, Gregory A.
    Carter, Gebra Cuyun
    Gilligan, Adrienne
    Saverno, Kim
    Zhu, Yajun Emily
    Price, Gregory L.
    Deluca, Angelo
    Smyth, Emily Nash Nash
    Koustenis, Andrew G.
    Huang, Yujing
    Schwartzberq, Lee S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [36] Comparison of ctDNA profiles from HR+/HER2-low and HR+/HER2-0 advanced breast cancer patients
    Dobric, N.
    Dandachi, N.
    Klocker, E. V.
    Suppan, C.
    Graf, R.
    Hasenleithner, S.
    Jost, P. J.
    Heitzer, E.
    Balic, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S387 - S387
  • [37] Clinical and economic benefit of genomic testing strategies to guide the treatment of patients with HR+/HER2-breast cancer in the US
    Gouldson, Mark
    Berdunov, Vlad
    Le, Quang Anh
    Millen, Steve
    Racz, Jennifer M.
    Arrick, Bradley A.
    Hartzfeld, Deborah
    Thakkar, Snehal Govind
    Heald, Brandie
    Russell, Christy A.
    Eymere, Sebastien
    Moyon, Camille
    Simmons, Harriet
    Carter, Gebra Cuyun
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [38] INT2 and ERBB2 amplification and ERBB2 expression in breast tumors from patients with different outcomes
    Pauley, RJ
    Gimotty, PA
    Paine, TJ
    Dawson, PJ
    Wolman, SR
    BREAST CANCER RESEARCH AND TREATMENT, 1996, 37 (01) : 65 - 76
  • [39] ERBB2 amplification in gastric cancer: a genomic insight into ethnic disparities
    Mirza, Muhammad Bilal
    Choi, Jungyoon
    Marincola Smith, Paula
    Baechle, Jordan J.
    Padmanabhan, Chandrasekhar
    Holowatyj, Andreana N.
    Shah, Shailja C.
    Guo, Xingyi
    Idrees, Kamran
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2024, 116 (11): : 1830 - 1833
  • [40] Comprehensive characterization of ERBB2 genomic alterations inlung cancer.
    El Zarif, Talal
    Stockhammer, Paul
    Schillo, Jacob
    Goldberg, Sarah B.
    Politi, Katerina A.
    Grant, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345